Señales en vivo de XBRANE.ST | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 11:29):

Stats
Volumen de hoy	12.16M
Volumen promedio	23.77M
Capitalización de mercado	307.11M
EPS	SEK0 ( 2024-02-26 )
Próxima fecha de ganancias	( SEK0 ) 2024-05-16
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-0.160
ATR14	SEK0 (0.00%)

Volumen Correlación

Largo: -0.14 (neutral)

Corto: -0.14 (neutral)

Signal:(52.256) Neutral

Xbrane Biopharma AB Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Xbrane Biopharma AB Correlación - Moneda/Commodity

0.61
( weak )

0.68
( moderate )

0.00
( neutral )

-0.62
( weak negative )

Xbrane Biopharma AB Finanzas

Annual	2023
Ingresos:	SEK238.73M
Beneficio Bruto:	SEK13.96M (5.85 %)
EPS:	SEK-1.530

FY	2023
Ingresos:	SEK238.73M
Beneficio Bruto:	SEK13.96M (5.85 %)
EPS:	SEK-1.530

FY	2022
Ingresos:	SEK57.62M
Beneficio Bruto:	SEK41.04M (71.23 %)
EPS:	SEK-0.760

FY	2021
Ingresos:	SEK0.00
Beneficio Bruto:	SEK0.00 (0.00 %)
EPS:	SEK-7.98

Financial Reports:

No articles found.

Xbrane Biopharma AB

Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and throat, bladder, and urinary tract cancer, as well as for renal cell carcinoma. The company has a strategic biosimilar development partnership with STADA Arzneimittel AG to evaluate development and commercialization collaborations around its Xcimzane and Xdivane preclinical biosimilars. Xbrane Biopharma AB (publ) was founded in 2008 and is headquartered in Solna, Sweden.